GENI Stock Genius Sports (GENI, $6.08) RSI Indicator left the oversold zone on September 22, 2026
at Tickeron.com
This is a signal that GENI's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 26 similar cases where GENI's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:
Momentum Indicator for GENI turns negative, indicating new downward trend
GENI saw its Momentum Indicator move below the 0 level on August 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 79 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for GENI turned negative on August 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 29 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
GENI moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GENI crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for GENI entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GENI's RSI Indicator exited the oversold zone, 21 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for GENI moved above the 200-day moving average on September 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +7.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GENI advanced for three days, in 204 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
GENI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.379) is normal, around the industry mean (1.386). P/E Ratio (59.172) is within average values for comparable stocks, (400.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (16.800). Dividend Yield (0.000) settles around the average of (0.013) among similar stocks. P/S Ratio (2.232) is also within normal values, averaging (69.903).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. GENI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.